The gene editing treatment for viral keratitis (BD111), developed based on BDmRNA delivery patent technology, has completed 3 human clinical trials of IIT. It is the only technology of Cas9 mRNA delivery by lentivirus in the world, and also the second human clinical research project of CRISPR-Cas9 gene editing treatment in human body in the world.

Herpes Simplex Virus Keratitis
Herpes Simplex Virus Keratitis
Herpes Simplex Virus (HSV) is the most common pathogen in humans. The infection is very common in the population. Until now, it has been a medical problem that has not been overcome-neither vaccines are available nor drugs can be cured.
HSV can be divided into two serotypes, HSV-1 and HSV-2 according to different antigenic characteristics. HSV-1 infection can cause many diseases. If the cornea of the eye is infected by HSV-1, it will cause herpetic stromal keratitis (HSK), which becomes the leading cause of infectious blindness.
Gene Therapy Of HSK

Through the fusion of gene editing and delivery technology, the BDgene research team created the world's first gene therapy delivery vector-viroid-mRNA (VLP-mRNA), and used this delivery technology to conduct preclinical research on CRISPR gene editing for the treatment of viral keratitis , Realized the retrograde transport from the cornea to the trigeminal ganglion, and finally cleared the HSV-1 virus library hidden in the ganglion.

Gene editing can inhibit the transport and replication of the HSV virus. It is hoped that it will become a new treatment for viral keratitis and solve the clinical problem of viral keratitis recurrence.


Research And Development Project


Building 10, No.55 Bixi Road, Minhang District, Shanghai,China